All
FDA Assigns Action Date for Arexvy to Prevent RSV in 50 to 59 Population
February 6th 2024The Prescription Drug User Fee Act date is June 7, 2024, for the additional indication of preventing respiratory syncytial virus (RSV) in adults aged 50 to 59 who are at increased risk. It is already approved for those over the age of 60.
New Study Planned for Bevacizumab to Treat AMD
December 20th 2023Outlook Therapeutics plans to begin a study in the first quarter of 2024 to address the issues identified in a FDA complete response letter. If approved, Lytenava would be the only bevacizumab product to specifically treat age-related macular degeneration.